Cardiac symptoms and anxiety disorders

Contributing factors and pharmacologic treatment

Rudolf Hoehn-Saric, Daniel R. McLeod

Research output: Contribution to journalArticle

Abstract

Anxiety may have deleterious effects on the cardiovascular system in persons who have, or are predisposed to have, cardiovascular disease. Contributing factors consist of the type of anxiety, constitutional characteristics and personality traits. The treatment of anxiety thus has a beneficial effect on patients with cardiovascular disease. However, anxiety reduction through medication, even if it includes subjective improvement in somatic symptoms, should not necessarily be equated with beneficial effects on the cardiovascular system. Three groups of medication used in the treatment of anxiety have different effects. Antidepressants lower psychic anxiety but may have the opposite effect on the cardiovascular system, whereas β-adrenergic blockers lower sympathetic tone without affecting psychic anxiety. Only benzodiazepines fulfill both functions. Since subjective reports of somatic, including cardiovascular, changes correlate poorly with physiologic changes, assessment of new medications should not rely on self-reported improvement in cardiac symptoms but should include objective measures as well.

Original languageEnglish (US)
JournalThe American Journal of Cardiology
Volume60
Issue number18
DOIs
StatePublished - Dec 28 1987

Fingerprint

Anxiety Disorders
Anxiety
Cardiovascular System
Therapeutics
Cardiovascular Diseases
Adrenergic Antagonists
Benzodiazepines
Antidepressive Agents
Personality

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Cardiac symptoms and anxiety disorders : Contributing factors and pharmacologic treatment. / Hoehn-Saric, Rudolf; McLeod, Daniel R.

In: The American Journal of Cardiology, Vol. 60, No. 18, 28.12.1987.

Research output: Contribution to journalArticle

@article{feb32ed250344c59b9501d428503f2bc,
title = "Cardiac symptoms and anxiety disorders: Contributing factors and pharmacologic treatment",
abstract = "Anxiety may have deleterious effects on the cardiovascular system in persons who have, or are predisposed to have, cardiovascular disease. Contributing factors consist of the type of anxiety, constitutional characteristics and personality traits. The treatment of anxiety thus has a beneficial effect on patients with cardiovascular disease. However, anxiety reduction through medication, even if it includes subjective improvement in somatic symptoms, should not necessarily be equated with beneficial effects on the cardiovascular system. Three groups of medication used in the treatment of anxiety have different effects. Antidepressants lower psychic anxiety but may have the opposite effect on the cardiovascular system, whereas β-adrenergic blockers lower sympathetic tone without affecting psychic anxiety. Only benzodiazepines fulfill both functions. Since subjective reports of somatic, including cardiovascular, changes correlate poorly with physiologic changes, assessment of new medications should not rely on self-reported improvement in cardiac symptoms but should include objective measures as well.",
author = "Rudolf Hoehn-Saric and McLeod, {Daniel R.}",
year = "1987",
month = "12",
day = "28",
doi = "10.1016/0002-9149(87)90686-2",
language = "English (US)",
volume = "60",
journal = "American Journal of Cardiology",
issn = "0002-9149",
publisher = "Elsevier Inc.",
number = "18",

}

TY - JOUR

T1 - Cardiac symptoms and anxiety disorders

T2 - Contributing factors and pharmacologic treatment

AU - Hoehn-Saric, Rudolf

AU - McLeod, Daniel R.

PY - 1987/12/28

Y1 - 1987/12/28

N2 - Anxiety may have deleterious effects on the cardiovascular system in persons who have, or are predisposed to have, cardiovascular disease. Contributing factors consist of the type of anxiety, constitutional characteristics and personality traits. The treatment of anxiety thus has a beneficial effect on patients with cardiovascular disease. However, anxiety reduction through medication, even if it includes subjective improvement in somatic symptoms, should not necessarily be equated with beneficial effects on the cardiovascular system. Three groups of medication used in the treatment of anxiety have different effects. Antidepressants lower psychic anxiety but may have the opposite effect on the cardiovascular system, whereas β-adrenergic blockers lower sympathetic tone without affecting psychic anxiety. Only benzodiazepines fulfill both functions. Since subjective reports of somatic, including cardiovascular, changes correlate poorly with physiologic changes, assessment of new medications should not rely on self-reported improvement in cardiac symptoms but should include objective measures as well.

AB - Anxiety may have deleterious effects on the cardiovascular system in persons who have, or are predisposed to have, cardiovascular disease. Contributing factors consist of the type of anxiety, constitutional characteristics and personality traits. The treatment of anxiety thus has a beneficial effect on patients with cardiovascular disease. However, anxiety reduction through medication, even if it includes subjective improvement in somatic symptoms, should not necessarily be equated with beneficial effects on the cardiovascular system. Three groups of medication used in the treatment of anxiety have different effects. Antidepressants lower psychic anxiety but may have the opposite effect on the cardiovascular system, whereas β-adrenergic blockers lower sympathetic tone without affecting psychic anxiety. Only benzodiazepines fulfill both functions. Since subjective reports of somatic, including cardiovascular, changes correlate poorly with physiologic changes, assessment of new medications should not rely on self-reported improvement in cardiac symptoms but should include objective measures as well.

UR - http://www.scopus.com/inward/record.url?scp=0023667294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023667294&partnerID=8YFLogxK

U2 - 10.1016/0002-9149(87)90686-2

DO - 10.1016/0002-9149(87)90686-2

M3 - Article

VL - 60

JO - American Journal of Cardiology

JF - American Journal of Cardiology

SN - 0002-9149

IS - 18

ER -